|
1
|
Königsberg R, Gneist M, Jahn-Kuch D,
Pfeiler G, Hager G, Hudec M, Dittrich C and Zeillinger R:
Circulating tumor cells in metastatic colorectal cancer: Efficacy
and feasibility of different enrichment methods. Cancer Lett.
293:117–123. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mavroudis D: Circulating cancer cells. Ann
Oncol. 21(Suppl 7): vii95–v100. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Khan MS, Kirkwood A, Tsigani T,
Garcia-Hernandez J, Hartley JA, Caplin ME and Meyer T: Circulating
tumor cells as prognostic markers in neuroendocrine tumors. J Clin
Oncol. 31:365–372. 2013. View Article : Google Scholar
|
|
4
|
Bidard FC, Peeters DJ, Fehm T, Nolé F,
Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz
JA, Stebbing J, et al: Clinical validity of circulating tumour
cells in patients with metastatic breast cancer: A pooled analysis
of individual patient data. Lancet Oncol. 15:406–414. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Buglione M1, Grisanti S, Almici C, Mangoni
M, Polli C, Consoli F, Verardi R, Costa L, Paiar F, Pasinetti N, et
al: Circulating tumour cells in locally advanced head and neck
cancer: preliminary report about their possible role in predicting
response to non-surgical treatment and survival. Eur J Cancer.
48:3019–3026. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lu CY, Tsai HL, Uen YH, Hu HM, Chen CW,
Cheng TL, Lin SR and Wang JY: Circulating tumor cells as a
surrogate marker for determining clinical outcome to mFOLFOX
chemotherapy in patients with stage III colon cancer. Br J Cancer.
108:791–797. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pavese JM and Bergan RC: Circulating tumor
cells exhibit a biologically aggressive cancer phenotype
accompanied by selective resistance to chemotherapy. Cancer Lett.
352:179–186. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tinhofer I, Konschak R, Stromberger C,
Raguse JD, Dreyer JH, Jöhrens K, Keilholz U and Budach V: Detection
of circulating tumor cells for prediction of recurrence after
adjuvant chemoradiation in locally advanced squamous cell carcinoma
of the head and neck. Ann Oncol. 25:2042–2047. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hamana K, Uzawa K, Ogawara K, Shiiba M,
Bukawa H, Yokoe H and Tanzawa H: Monitoring of circulating
tumour-associated DNA as a prognostic tool for oral squamous cell
carcinoma. Br J Cancer. 92:2181–2184. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gröbe A, Blessmann M, Hanken H, Friedrich
RE, Schön G, Wikner J, Effenberger KE, Kluwe L, Heiland M, Pantel
K, et al: Prognostic relevance of circulating tumor cells in blood
and disseminated tumor cells in bone marrow of patients with
squamous cell carcinoma of the oral cavity. Clin Cancer Res.
20:425–433. 2014. View Article : Google Scholar
|
|
11
|
Uzawa K, Baba T, Uchida F, Yamatoji M,
Kasamatsu A, Sakamoto Y, Ogawara K, Shiiba M, Bukawa H and Tanzawa
H: Circulating tumor-derived mutant mitochondrial DNA: A predictive
biomarker of clinical prognosis in human squamous cell carcinoma.
Oncotarget. 3:670–677. 2012.PubMed/NCBI
|
|
12
|
Saito K, Uzawa K, Kasamatsu A, Shinozuka
K, Sakuma K, Yamatoji M, Shiiba M, Shino Y, Shirasawa H and Tanzawa
H: Oncolytic activity of Sindbis virus in human oral squamous
carcinoma cells. Br J Cancer. 101:684–690. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR' for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar :
|
|
14
|
He Y, Wu J, Dressman DC, Iacobuzio-Donahue
C, Markowitz SD, Velculescu VE, Diaz LA Jr, Kinzler KW, Vogelstein
B and Papadopoulos N: Heteroplasmic mitochondrial DNA mutations in
normal and tumour cells. Nature. 464:610–614. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cen P, Ni X, Yang J, Graham DY and Li M:
Circulating tumor cells in the diagnosis and management of
pancreatic cancer. Biochim Biophys Acta. 1826:350–356.
2012.PubMed/NCBI
|
|
16
|
Lianidou ES, Mavroudis D and Georgoulias
V: Clinical challenges in the molecular characterization of
circulating tumour cells in breast cancer. Br J Cancer.
108:2426–2432. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Romero-Laorden N, Olmos D, Fehm T,
Garcia-Donas J and Diaz-Padilla I: Circulating and disseminated
tumor cells in ovarian cancer: A systematic review. Gynecol Oncol.
133:632–639. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bozec A, Ilie M, Dassonville O, Long E,
Poissonnet G, Santini J, Chamorey E, Ettaiche M, Chauvière D,
Peyrade F, et al: Significance of circulating tumor cell detection
using the CellSearch system in patients with locally advanced head
and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol.
270:2745–2749. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Driemel C, Kremling H, Schumacher S, Will
D, Wolters J, Lindenlauf N, Mack B, Baldus SA, Hoya V, Pietsch JM,
et al: Context-dependent adaption of EpCAM expression in early
systemic esophageal cancer. Oncogene. 33:4904–4915. 2014.
View Article : Google Scholar
|
|
20
|
Wirtschafter A, Benninger MS, Moss TJ,
Umiel T, Blazoff K and Worsham MJ: Micrometastatic tumor detection
in patients with head and neck cancer: A preliminary report. Arch
Otolaryngol Head Neck Surg. 128:40–43. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nawroz H, Koch W, Anker P, Stroun M and
Sidransky D: Microsatellite alterations in serum DNA of head and
neck cancer patients. Nat Med. 2:1035–1037. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mehra N, Penning M, Maas J, van Daal N,
Giles RH and Voest EE: Circulating mitochondrial nucleic acids have
prognostic value for survival in patients with advanced prostate
cancer. Clin Cancer Res. 13:421–426. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kohler C, Radpour R, Barekati Z,
Asadollahi R, Bitzer J, Wight E, Bürki N, Diesch C, Holzgreve W and
Zhong XY: Levels of plasma circulating cell free nuclear and
mitochondrial DNA as potential biomarkers for breast tumors. Mol
Cancer. 8:1052009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ellinger J, Müller DC, Müller SC, Hauser
S, Heukamp LC, von Ruecker A, Bastian PJ and Walgenbach-Brunagel G:
Circulating mitochondrial DNA in serum: A universal diagnostic
biomarker for patients with urological malignancies. Urol Oncol.
30:509–515. 2012. View Article : Google Scholar
|
|
25
|
Tsai NW, Lin TK, Chen SD, Chang WN, Wang
HC, Yang TM, Lin YJ, Jan CR, Huang CR, Liou CW, et al: The value of
serial plasma nuclear and mitochondrial DNA levels in patients with
acute ischemic stroke. Clin Chim Acta. 412:476–479. 2011.
View Article : Google Scholar
|
|
26
|
Bliksøen M, Mariero LH, Ohm IK, Haugen F,
Yndestad A, Solheim S, Seljeflot I, Ranheim T, Andersen GØ, Aukrust
P, et al: Increased circulating mitochondrial DNA after myocardial
infarction. Int J Cardiol. 158:132–134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kung CT, Hsiao SY, Tsai TC, Su CM, Chang
WN, Huang CR, Wang HC, Lin WC, Chang HW, Lin YJ, et al: Plasma
nuclear and mitochondrial DNA levels as predictors of outcome in
severe sepsis patients in the emergency room. J Transl Med.
10:1302012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Qiu C, Hevner K, Enquobahrie DA and
Williams MA: A case-control study of maternal blood mitochondrial
DNA copy number and preeclampsia risk. Int J Mol Epidemiol Genet.
3:237–244. 2012.PubMed/NCBI
|
|
29
|
Lai CH, Huang SF, Liao CT, Chen IH, Wang
HM and Hsieh LL: Clinical significance in oral cavity squamous cell
carcinoma of pathogenic somatic mitochondrial mutations. PLoS One.
8:e655782013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kumazaki T, Sakano T, Yoshida T, Hamada K,
Sumida H, Teranishi Y, Nishiyama M and Mitsui Y: Enhanced
expression of mitochondrial genes in senescent endothelial cells
and fibroblasts. Mech Ageing Dev. 101:91–99. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu VW, Shi HH, Cheung AN, Chiu PM, Leung
TW, Nagley P, Wong LC and Ngan HY: High incidence of somatic
mitochondrial DNA mutations in human ovarian carcinomas. Cancer
Res. 61:5998–6001. 2001.PubMed/NCBI
|
|
32
|
Kumimoto H1, Yamane Y, Nishimoto Y, Fukami
H, Shinoda M, Hatooka S and Ishizaki K: Frequent somatic mutations
of mitochondrial DNA in esophageal squamous cell carcinoma. Int J
Cancer. 108:228–231. 2004. View Article : Google Scholar
|
|
33
|
Prior SL, Griffiths AP, Baxter JM, Baxter
PW, Hodder SC, Silvester KC and Lewis PD: Mitochondrial DNA
mutations in oral squamous cell carcinoma. Carcinogenesis.
27:945–950. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sun W, Zhou S, Chang SS, McFate T, Verma A
and Califano JA: Mitochondrial mutations contribute to HIF1alpha
accumulation via increased reactive oxygen species and up-regulated
pyruvate dehydrogenease kinase 2 in head and neck squamous cell
carcinoma. Clin Cancer Res. 15:476–484. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Singh RK, Srivastava A, Kalaiarasan P,
Manvati S, Chopra R and Bamezai RN: mtDNA germ line variation
mediated ROS generates retrograde signaling and induces
pro-cancerous metabolic features. Sci Rep. 4:65712014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bai RK, Leal SM, Covarrubias D, Liu A and
Wong LJ: Mitochondrial genetic background modifies breast cancer
risk. Cancer Res. 67:4687–4694. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Covarrubias D, Bai RK, Wong LJ and Leal
SM: Mitochondrial DNA variant interactions modify breast cancer
risk. J Hum Genet. 53:924–928. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Czarnecka AM, Krawczyk T, Zdrozny M,
Lubiński J, Arnold RS, Kukwa W, Scińska A, Golik P, Bartnik E and
Petros JA: Mitochondrial NADH-dehydrogenase subunit 3 (ND3)
polymorphism (A10398G) and sporadic breast cancer in Poland. Breast
Cancer Res Treat. 121:511–518. 2010. View Article : Google Scholar
|
|
39
|
Kandel ES: Mutations in circulating
mitochondrial DNA: Cassandra of oral cancer? Oncotarget. 3:664–665.
2012.PubMed/NCBI
|
